SGLT2 Inhibitors in Combination Therapy: From Mechanisms to Clinical Considerations in Type 2 Diabetes Management.

@article{Baar2018SGLT2II,
  title={SGLT2 Inhibitors in Combination Therapy: From Mechanisms to Clinical Considerations in Type 2 Diabetes Management.},
  author={Micha{\"e}l J.B. van Baar and Charlotte C. van Ruiten and Marcel H.A. Muskiet and Liselotte van Bloemendaal and Richard G. Ijzerman and Dani{\"e}l H. van Raalte},
  journal={Diabetes care},
  year={2018},
  volume={41 8},
  pages={
          1543-1556
        }
}
The progressive nature of type 2 diabetes (T2D) requires practitioners to periodically evaluate patients and intensify glucose-lowering treatment once glycemic targets are not attained. With guidelines moving away from a one-size-fits-all approach toward setting patient-centered goals and allowing flexibility in choosing a second-/third-line drug from the growing number of U.S. Food and Drug Administration-approved glucose-lowering agents, keen personalized management in T2D has become a… CONTINUE READING
167
Twitter Mentions

Citations

Publications citing this paper.
SHOWING 1-10 OF 14 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 115 REFERENCES

Comparable glycaemic control with once weekly dulaglutide versus insulin glargine, both combined with lispro, in type 2 diabetes and chronic kidney disease

  • KR Tuttle, MC Lakshmanan, JL Gross
  • Diabetologia
  • 2017
VIEW 2 EXCERPTS
HIGHLY INFLUENTIAL

Do we knowthe truemechanismof actionof theDPP - 4 inhibitors ?

  • K Esposito, P Chiodini, MI Maiorino
  • Diabetes Obes Metab
  • 2018

Do we knowthe truemechanismof actionof theDPP-4 inhibitors? Diabetes

  • ES Andersen, CF Deacon, JJ. Holst
  • Obes Metab
  • 2018
VIEW 1 EXCERPT

Effects of the sodium–glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b–4 chronic kidney disease